Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN versus SULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN versus SULLA.
GANTRISIN vs SULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
100 mg orally once daily, increased to 200 mg daily if needed.
None Documented
None Documented
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
6-12 hours; prolonged in renal impairment (up to 30 hours)
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic